Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services logo
$392.00 -2.03 (-0.52%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$396.52 +4.53 (+1.16%)
As of 10/23/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
2
Buy
12

Based on 14 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, and 12 have given a buy rating for WST.

Consensus Price Target

$391.17
-0.21% Downside
According to the 14 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $391.17. The highest price target for WST is $447.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted downside of -0.21% from the current price of $392.00.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
6 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$391.17$382.00$363.17$347.63
Forecasted Upside-0.21% Downside3.07% Upside9.54% Upside16.60% Upside
Consensus RatingModerate BuyModerate BuyBuyModerate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesHealthcare CompaniesBroader Market
Consensus Rating Score
2.86
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-0.21% Downside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent WST News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/13/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Brendan Smith
Not Rated
Boost TargetBuy$410.00 ➝ $420.00+13.94%
10/7/2026
Barclays PLC logo
Barclays
3 of 5 stars
Luke Sergott
Luke Sergott
5 of 5 stars
Boost TargetOverweight$400.00 ➝ $440.00+17.97%
9/22/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
UpgradeEqual Weight ➝ Overweight$365.00 ➝ $400.00+10.59%
9/9/2026Boost TargetBuy$340.00 ➝ $415.00+22.22%
8/12/2026 DowngradeStrong-Buy ➝ Hold
8/7/2026 UpgradeHold (C) ➝ Hold (C+)
8/3/2026Boost TargetBuy$400.00 ➝ $412.00+20.81%
7/27/2026Reiterated RatingOutperform$425.00+28.46%
7/13/2026Initiated CoverageOutperform$447.00+26.38%
7/2/2026Boost TargetOverweight$350.00 ➝ $390.00+6.84%
6/2/2026Reiterated RatingOverweight$360.00+13.97%
6/1/2026Initiated CoverageOutperform$375.00+18.72%
2/13/2026Reiterated RatingBuy$315.00+29.70%
2/10/2026Reiterated RatingBuy$295.00+17.85%
9/15/2025Set Target$311.00+20.67%
12/13/2024 Boost TargetBuy$350.00 ➝ $355.00+8.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:44 PM ET.


Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 24, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • West Pharmaceutical Services, Inc. recently declared a quarterly dividend of $0.26 per share, representing an 18.2% increase from the previous quarter's $0.22 payment, marking the thirty-fourth consecutive annual increase in the company's dividend payout.
  • The company demonstrated strong financial performance in its most recent quarterly report, with revenue of $872.30 million exceeding analyst estimates of $839.98 million and earnings per share of $2.37 beating the consensus estimate of $2.08, indicating robust demand for its pharmaceutical packaging components.
  • West Pharmaceutical Services, Inc. has raised its full-year 2026 earnings per share guidance to a range of $8.85 to $9.05, which is significantly higher than the consensus estimate of $8.61, suggesting management confidence in continued growth and operational efficiency.
  • Institutional investors are showing renewed interest in the stock, with Robeco Institutional Asset Management B.V. increasing its stake by 75.2% during the third quarter, signaling strong confidence from major asset managers in the company's long-term prospects.
  • The stock is currently trading at $392.00, which is near its 52-week high of $397.15, reflecting a strong upward momentum and outperformance relative to its industry peers over the past year.

West Pharmaceutical Services
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • Wall Street Zen recently downgraded West Pharmaceutical Services, Inc. from a "buy" rating to a "hold" rating, suggesting that some analysts believe the stock's recent gains may have priced in much of the positive news and that further upside is limited.
  • The company's current price-to-earnings ratio of 46.14 is relatively high, which may indicate that the stock is overvalued compared to its historical averages or industry peers, potentially limiting future returns for new investors.
  • Insider selling has been notable recently, with Vice President Annette Favorite selling a total of 15,659 shares over the last three months, which could signal that company executives are taking advantage of the stock's recent high prices to reduce their personal holdings.
  • Some financial analyses suggest that West Pharmaceutical Services, Inc. stock could be 17% overvalued as cash flow falls short of expectations, raising concerns about the sustainability of its current valuation and future earnings growth.
  • The stock's beta of 1.13 indicates that it is slightly more volatile than the overall market, meaning investors may experience greater price swings and higher risk compared to less volatile investments.

WST Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $391.17, with a high forecast of $447.00 and a low forecast of $295.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted downside of -0.21% based on their 12-month stock forecasts.

Over the previous 90 days, West Pharmaceutical Services's stock had 2 upgrades and 1 downgrade by analysts.

West Pharmaceutical Services has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, TD Cowen, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like West Pharmaceutical Services more than other "healthcare" companies. The consensus rating for West Pharmaceutical Services is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how WST compares to other companies.


MarketBeat monitors more than a dozen sources for West Pharmaceutical Services analyst ratings, with the most recent rating issued on 10/13/2026.
From Our Partners